Omontys Safety Still a Problem for Nondialysis Patients (CME/CE)
(MedPage Today) -- The anemia drug peginesatide (Omontys) in chronic kidney disease patients not undergoing hemodialysis may carry an increased risk of cardiovascular events, two paired trials suggested.
Tags:
Omontys Safety Still a Problem for Nondialysis Patients (CME/CE),
Cardiovascular Disease Latest News